PCRXPacira BioSciences, Inc.

PCRX Stock Price, Valuation & Chart | Pacira BioSciences, Inc.

$26.580+0.11 (+0.42%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic PCRX intrinsic value PCRX calculated fair value vs price

Overview Financials Dividends Ratios

PCRX Historical price chart

PCRX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.05B

PE Ratio10.22

EPS2.6

Trading Volume574.62K

Today's High/Low26.91/26.25

Dividend Yield0.00

52 Week High/Low27.66/18.8

Shares Outstanding39.34M

PCRX Financial Statement

PCRX Analyst ratings

PCRX Analysis & performance metrics

PCRX Company profile

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The…

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to…

PCRX Management team

Name

Position

Susan Mesco

Head of Investor Relations

Lauren Bullaro Riker

Principal Accounting Officer & Senior Vice President of Finance

Charles A. Reinhart III, CPA, M.B.A.

Executive Officer

Anthony Molloy III, Esq.

Chief Legal & Compliance Officer

Christopher C. Young

Chief Manufacturing Officer

Kristen Williams Esq., J.D.

Chief Administrative Officer & Secretary

David M. Stack

Advisor

Jonathan Slonin M.D.

Chief Medical Officer

Name

Position

Susan Mesco

Head of Investor Relations

Lauren Bullaro Riker

Principal Accounting Officer & Senior Vice President of Finance

Charles A. Reinhart III, CPA, M.B.A.

Executive Officer

Anthony Molloy III, Esq.

Chief Legal & Compliance Officer

Christopher C. Young

Chief Manufacturing Officer

Kristen Williams Esq., J.D.

Chief Administrative Officer & Secretary

David M. Stack

Advisor

Jonathan Slonin M.D.

Chief Medical Officer

Management Team

Susan Mesco

Head of Investor Relations

Lauren Bullaro Riker

Principal Accounting Officer & Senior Vice President of Finance

Charles A. Reinhart III, CPA, M.B.A.

Executive Officer

Anthony Molloy III, Esq.

Chief Legal & Compliance Officer

Christopher C. Young

Chief Manufacturing Officer

Kristen Williams Esq., J.D.

Chief Administrative Officer & Secretary

David M. Stack

Advisor

Jonathan Slonin M.D.

Chief Medical Officer

Management

Susan Mesco

Head of Investor Relations

Lauren Bullaro Riker

Principal Accounting Officer & Senior Vice President of Finance

Charles A. Reinhart III, CPA, M.B.A.

Executive Officer

Anthony Molloy III, Esq.

Chief Legal & Compliance Officer

Christopher C. Young

Chief Manufacturing Officer

Kristen Williams Esq., J.D.

Chief Administrative Officer & Secretary

David M. Stack

Advisor

Jonathan Slonin M.D.

Chief Medical Officer

Total 8 executives

PCRX Frequently asked questions

What is Pacira BioSciences, Inc. (PCRX) Stock Price?

Current stock price of Pacira BioSciences, Inc. (PCRX) stock is $26.580. The stock price is +0.42% higher in the session. The intraday range can be seen from this page. Volume of Pacira BioSciences, Inc. (PCRX) stock is 574.62K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Pacira BioSciences, Inc. (PCRX) stock price going up or down today?

The stock price of Pacira BioSciences, Inc. (PCRX) can change with earnings, company news, and overall market sentiment. Pacira BioSciences, Inc. operates in the Healthcare / Drug Manufacturers - Specialty & Generic market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Pacira BioSciences, Inc. stock expensive at its current price?

Whether Pacira BioSciences, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PCRX on this page is 10.22. EPS on this page is 2.60. Compare those figures with peers and growth expectations before deciding if the current Pacira BioSciences, Inc. price is justified.

How has the stock price of Pacira BioSciences, Inc. (PCRX) performed historically?

Historical performance for Pacira BioSciences, Inc. (PCRX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PCRX reacted to past earnings and market events.

Should I buy Pacira BioSciences, Inc. (PCRX) stock, at this price?

Buying Pacira BioSciences, Inc. (PCRX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.